Reata Pharmaceuticals (NASDAQ:RETA) is scheduled to be releasing its earnings data before the market opens on Thursday, August 8th. Analysts expect Reata Pharmaceuticals to post earnings of ($1.12) per share for the quarter.
Reata Pharmaceuticals (NASDAQ:RETA) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.01). The firm had revenue of $7.77 million during the quarter, compared to analyst estimates of $7.92 million. On average, analysts expect Reata Pharmaceuticals to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.
Shares of NASDAQ RETA traded down $2.90 during mid-day trading on Tuesday, hitting $80.98. The company had a trading volume of 2,914 shares, compared to its average volume of 170,899. The stock has a market cap of $2.56 billion, a P/E ratio of -28.22 and a beta of 2.31. The company has a quick ratio of 5.19, a current ratio of 5.19 and a debt-to-equity ratio of 5.23. Reata Pharmaceuticals has a 1-year low of $47.50 and a 1-year high of $104.53. The business’s 50-day moving average price is $88.95.
Several equities analysts recently commented on RETA shares. Zacks Investment Research lowered Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, July 11th. BidaskClub raised Reata Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, July 31st. Finally, Citigroup increased their target price on Reata Pharmaceuticals from $185.00 to $190.00 and gave the company a “buy” rating in a report on Friday, May 31st. One investment analyst has rated the stock with a sell rating, five have issued a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $140.50.
About Reata Pharmaceuticals
Reata Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (Bard) for the treatment of patients with chronic kidney disease caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; and omaveloxolone that is Phase II clinical trial for the treatment of patients with Friedreich's ataxia It is also developing RTA 901, which completed Phase 1 clinical trials for the treatment of orphan neurological indications; and RORgT Inhibitors that are in the preclinical development phase for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases.
Further Reading: Swap
Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.